Metabolism, excretion, and pharmacokinetics of [14c]-radiolabeled aleglitazar: a phase I, nonrandomized, open-label, single-center, single-dose study in healthy male volunteers.

No abstract is available for this paper.

• Publication year

  2012

• Venue

  Clinical Therapeutics

• Publication date

  2012-02-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/j.clinthera.2011.12.009PMID 22244809
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Pharmacokinetics, efficacy and safety of aleglitazar for the treatment of type 2 diabetes with high cardiovascular risk

  2011cited by this paper
• Effects of high dose aleglitazar on renal function in patients with type 2 diabetes.

  2011cited by this paper
• Published norms underestimate the health-related quality of life among persons with type 2 diabetes.

  2011cited by this paper
• Effects of aleglitazar, a balanced dual peroxisome proliferator-activated receptor α/γ agonist on glycemic and lipid parameters in a primate model of the metabolic syndrome

  2011cited by this paper
• Pharmacokinetics, Pharmacodynamics, and Tolerability of Aleglitazar in Patients With Type 2 Diabetes: Results From a Randomized, Placebo‐Controlled Clinical Study

  2010cited by this paper
• Effect of Rosiglitazone on Progression of Coronary Atherosclerosis in Patients With Type 2 Diabetes Mellitus and Coronary Artery Disease: The Assessment on the Prevention of Progression by Rosiglitazone on Atherosclerosis in Diabetes Patients With Cardiovascular History Trial

  2010cited by this paper
• Fibrates, Glitazones, and Peroxisome Proliferator–Activated Receptors

  2010cited by this paper
• The global burden of diabetes and its complications: an emerging pandemic

  2010cited by this paper
• Effect of the dual peroxisome proliferator-activated receptor-alpha/gamma agonist aleglitazar on risk of cardiovascular disease in patients with type 2 diabetes (SYNCHRONY): a phase II, randomised, dose-ranging study.

  2009cited by this paper
• Pleiotropic effects of thiazolidinediones on traditional and non‐traditional atherosclerotic risk factors

  2009cited by this paper
• Aleglitazar, a new, potent, and balanced dual PPARalpha/gamma agonist for the treatment of type II diabetes.

  2009cited by this paper
• Fibrates and future PPARα agonists in the treatment of cardiovascular disease

  2008cited by this paper
• Comparison of pioglitazone vs glimepiride on progression of coronary atherosclerosis in patients with type 2 diabetes: the PERISCOPE randomized controlled trial.

  2008cited by this paper
• Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes.

  2007cited by this paper
• Pharmacotherapy for the Treatment of Patients with Type 2 Diabetes Mellitus: Rationale and Specific Agents

  2007cited by this paper
• Evolution of Peroxisome Proliferator-Activated Receptor Agonists

  2007cited by this paper
• Effect of pioglitazone compared with glimepiride on carotid intima-media thickness in type 2 diabetes: a randomized trial.

  2006cited by this paper
• Inflammation and Atherothrombosis: From Population Biology and Bench Research to Clinical Practice

  2006cited by this paper
• Thiazolidinediones.

  2004cited by this paper
• Pharmacokinetics and metabolism of tesaglitazar, a novel dual-acting peroxisome proliferator-activated receptor alpha/gamma agonist, after a single oral and intravenous dose in humans.

  2004cited by this paper
• PHARMACOKINETICS AND METABOLISM OF TESAGLITAZAR, A NOVEL DUAL-ACTING PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR (cid:1) / (cid:2) AGONIST, AFTER A SINGLE ORAL AND INTRAVENOUS DOSE IN HUMANS

  2004cited by this paper
• Medical significance of peroxisome proliferator-activated receptors.

  1999cited by this paper
• Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction.

  1998cited by this paper
• PPAR-gamma: adipogenic regulator and thiazolidinedione receptor.

  1998cited by this paper
• Prevention and treatment of renal disease in insulin-dependent diabetes mellitus.

  1990cited by this paper

• Phenoxyalkyl cyclic and acyclic amine derivatives: what do they teach us about scaffold-based drug design?

  2024cites this paper
• Exposure and response analysis of aleglitazar on cardiovascular risk markers and safety outcomes: An analysis of the AleCardio trial

  2019cites this paper
• Physicochemical properties of dietary phytochemicals can predict their passive absorption in the human small intestine

  2017cites this paper
• Non‐clinical safety evaluation and risk assessment to human of aleglitazar, a dual PPAR &agr;/&ggr; agonist, and its major human metabolite

  2017cites this paper
• The Effect of Aleglitazar on the Pharmacokinetics and Pharmacodynamics of S- and R-Warfarin in Healthy Male Subjects

  2014cites this paper
• Examining the safety of PPAR agonists – current trends and future prospects

  2013cites this paper